1. Home
  2. EFSI vs LRMR Comparison

EFSI vs LRMR Comparison

Compare EFSI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

N/A

Current Price

$45.97

Market Cap

252.1M

Sector

Finance

ML Signal

N/A

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$2.72

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EFSI
LRMR
Founded
1881
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.1M
253.5M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
EFSI
LRMR
Price
$45.97
$2.72
Analyst Decision
Hold
Strong Buy
Analyst Count
3
11
Target Price
★ $47.00
$14.40
AVG Volume (30 Days)
38.2K
★ 1.4M
Earning Date
10-22-2026
11-24-2026
Dividend Yield
★ 2.70%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.49
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.52
N/A
P/E Ratio
$18.39
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$31.44
$1.92
52 Week High
$48.17
$6.42

Technical Indicators

Market Signals
Indicator
EFSI
LRMR
Relative Strength Index (RSI) 52.77 51.48
Support Level $45.07 $1.92
Resistance Level $47.73 $4.19
Average True Range (ATR) 1.11 0.24
MACD -0.06 0.07
Stochastic Oscillator 40.09 75.38

Price Performance

Historical Comparison
EFSI
LRMR

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Share on Social Networks: